USA Archives

News and Trends 4 Aug 2022

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health. The recombinant enzyme is a double-mutant cocaine esterase 200 mg intravenous (IV) solution and treats cocaine intoxication, which refers to the state of when cocaine […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series. “We […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

Gilead Sciences set to acquire MiroBio for $405M

California-headquartered Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotech company, have announced the companies have entered into a definitive agreement with Gilead acquiring MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

The eyes have it – Visiox Pharma closes $7M seed round

Visiox Pharma, LLC, a privately-funded U.S. biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, has announced the closing of a $7 million seed round of financing. The raise was funded by the Founding Partners and a group of ophthalmic industry leaders. […]

August 3, 2022 - 2 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 3 Aug 2022

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […]

August 3, 2022 - 4 minutesmins - By Liza Laws

car-t therapy, combination therapy, car-t cell therapy, cancer therapy, blood cancer

More News! 3 Aug 2022

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

US-based Allarity Therapeutics has made a decision to change tack and focus on combination therapy approaches while making the most of its current assets. The company says the new strategy, driven by its board of directors, aligns with the ongoing shift in oncology standard-of-care moving away from monotherapies. Instead it will veer towards more promising […]

August 3, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery

AbCellera and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ track record in forming innovative biotech companies, and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines […]

August 3, 2022 - 2 minutesmins - By Jim Cornall

More News! 3 Aug 2022

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […]

August 3, 2022 - 2 minutesmins - By Liza Laws

cancer shutterstock immunotherapy deep science ventures

News and Trends 2 Aug 2022

IDRx launches with $122M to treat cancer with precision combination therapies

DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

Gilead Sciences set to acquire MiroBio for $405M

RoslinCT and Lykan Bioscience combine to create cell therapy CDMO

The eyes have it – Visiox Pharma closes $7M seed round

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

IDRx launches with $122M to treat cancer with precision combination therapies

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!